Moneycontrol PRO
HomeNewsIndiaCipla, Jubilant to face action if they fail to fulfill supply obligation of Remdesivir within 24 hours: Karnataka govt

Cipla, Jubilant to face action if they fail to fulfill supply obligation of Remdesivir within 24 hours: Karnataka govt

The Karnataka government has said that the Centre had directed Jubilant Ltd to supply 32,000 Remdesevir vials to the state by May 9. However, Karnataka has only received 17,601 vials from the company as of May 8.

May 11, 2021 / 21:13 IST
Source: Reuters

The Karnataka government on May 11 warned Cipla, Jubilant with legal action if they fail to fulfill the supply obligation of Remdesivir within 24 hours.

The Karnataka government has said that the Centre had directed Jubilant Ltd to supply 32,000 Remdesevir vials to the state by May 9. However, Karnataka has only received 17,601 vials from the company as of May 8.

Similarly, the Centre had directed Cipla Ltd to supply 30,000 vials of Remdesivir by May 9, but the state received only 10,840 vials as of May 8.

Failure of the pharma firms in supplying the requisite quantity as directed by the Government of India severely impacted the treatment of coronavirus patients requiring Remdesivir vials, the state government said. It constrained the state’s capacity to provide timely and effective treatment to infected patients.

Cipla and Jubilant have been further directed to provide day-to-day supply quantity commitments of Remdesivir vials as allotted by the Centre to Karnataka.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

Karnataka on May 11 reported 39,510 new COVID-19 cases, 480 deaths, and 22,584 discharges. The total number of active coronavirus cases in the state now stands at 5,87,452 and the total coronavirus tally is 20,13,193. As many as 19,852 COVID-19 patients have died in Karnataka so far, while 14,05,869 COVID-19 patients have recovered from the disease since the outbreak of the pandemic.

Follow our coverage of the coronavirus crisis here

Moneycontrol News
first published: May 11, 2021 08:53 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347